Approach to diabetes in pregnancy: Clinical sciences

Last updated: February 20, 2024

Approach to diabetes in pregnancy: Clinical sciences

MPAN 690 Week 1 - Obstetrics & Gynecology

MPAN 690 Week 1 - Obstetrics & Gynecology

Anatomy of the breast
Anatomy clinical correlates: Breast
Approach to a breast mass and asymmetry: Clinical sciences
Benign breast conditions: Pathology review
Fibrocystic breast changes
Fibrocystic breast changes: Clinical sciences
Breast papilloma: Clinical sciences
Fibroadenoma: Clinical sciences
Breast cyst: Clinical sciences
Approach to nipple discharge: Clinical sciences
Approach to breast pain (mastalgia): Clinical sciences
Mastitis: Clinical sciences
Breast abscess: Clinical sciences
Breast cancer
Breast cancer screening: Clinical sciences
Breast cancer: Pathology review
Ductal carcinoma in situ: Clinical sciences
Invasive ductal carcinoma: Clinical sciences
Lobular carcinoma in situ: Clinical sciences
Invasive lobular carcinoma: Clinical sciences
Inflammatory breast cancer: Clinical sciences
Paget disease of the breast
Well-patient care (GYN): Clinical sciences
Cervix and vagina histology
Cervical cancer
Cervical cancer screening: Clinical sciences
Cervical dysplasia and cervical cancer: Clinical sciences
Cervical cancer: Pathology review
Vulvar dysplasia and vulvar cancer: Clinical sciences
Approach to vaginal discharge: Clinical sciences
Sexually transmitted infection screening (GYN): Clinical sciences
Sexually transmitted infection screening (Family medicine): Clinical sciences
Sexually transmitted infections: Vaginitis and cervicitis: Pathology review
Candida
Vulvovaginal candidiasis: Clinical sciences
Gardnerella vaginalis (Bacterial vaginosis)
Bacterial vaginosis: Clinical sciences
Trichomonas vaginalis
Vaginal trichomoniasis: Clinical sciences
Chlamydia trachomatis
Chlamydia trachomatis infection: Clinical sciences
Neisseria gonorrhoeae
Neisseria gonorrhoeae infection: Clinical sciences
Pelvic inflammatory disease
Pelvic inflammatory disease: Clinical sciences
Reversible contraception: Clinical sciences
Permanent contraception (sterilization): Clinical sciences
Emergency contraception: Clinical sciences
Approach to dysmenorrhea: Clinical sciences
Primary dysmenorrhea: Clinical sciences
Approach to abnormal uterine bleeding in reproductive-aged patients: Clinical sciences
Approach to acute pelvic pain (GYN): Clinical sciences
Approach to chronic pelvic pain (GYN): Clinical sciences
Uterine disorders: Pathology review
Uterine fibroid
Stress, urge, overflow, and mixed urinary incontinence (GYN): Clinical sciences
Preconception care: Clinical sciences
Pregnancy
Ectopic pregnancy
Ectopic pregnancy: Clinical sciences
Complications during pregnancy: Pathology review
Anemia in pregnancy: Clinical sciences
Nausea and vomiting of pregnancy: Clinical sciences
Asthma in pregnancy: Clinical sciences
Cholestasis of pregnancy: Clinical sciences
Diabetes in pregnancy (GDM, T1DM, and T2DM): Clinical sciences
Approach to diabetes in pregnancy: Clinical sciences
Approach to hypertensive disorders in pregnancy: Clinical sciences
Chronic hypertension in pregnancy: Clinical sciences
Venous thromboembolism in pregnancy: Clinical sciences
Urinary tract infections and kidney stones in pregnancy: Clinical sciences
Group B streptococcus (GBS) colonization in pregnancy: Clinical sciences
Herpes simplex virus infection in pregnancy: Clinical sciences
Cytomegalovirus (CMV), parvovirus B19, varicella zoster, and toxoplasmosis infection in pregnancy: Clinical sciences
Alcohol, tobacco, cannabinoid, and substance use in pregnancy: Clinical sciences
Perinatal depression and anxiety: Clinical sciences
Hemoglobinopathies in pregnancy: Clinical sciences
Abdominal trauma in pregnancy: Clinical sciences
Early pregnancy loss: Clinical sciences
Miscarriage
Late-term and postterm pregnancy: Clinical sciences
Antepartum care (first trimester): Clinical sciences
Approach to first trimester bleeding: Clinical sciences
Antepartum care (second trimester): Clinical sciences
Antepartum care (third trimester): Clinical sciences
Approach to third trimester bleeding: Clinical sciences
Placenta previa and vasa previa: Clinical sciences
Placenta previa
Prelabor rupture of membranes: Clinical sciences
Preterm labor: Clinical sciences
Fetal growth restriction: Clinical sciences
Uterine stimulants and relaxants
Therapeutic and induced abortions: Clinical sciences
Menopause
Perimenopause, menopause, and primary ovarian insufficiency: Clinical sciences
Approach to postmenopausal bleeding: Clinical sciences

Decision-Making Tree

Questions

USMLE® Step 2 style questions USMLE

0 of 3 complete

Start
A 29-year-old woman, gravida 2 para 1 at 26 weeks of gestation presents for routine prenatal care. She has no significant past medical history and her first pregnancy was uncomplicated. The patient undergoes a 50-gram glucose challenge test and the 1-hour plasma glucose level is 145 mg/dL. A 100-gram oral glucose tolerance test is performed and shows the following glucose values: fasting95 mg/dL, 1-hour 190 mg/dL, 2-hour 155 mg/dL, and 3-hour 145 mg/dL. The patient subsequently undergoes intensive dietary modifications and initiates regular moderate physical activity. Her self-monitoring of blood glucose shows postprandial glucose levels ranging from 95-115 mg/dL. Based on these results, which of the following is the most appropriate next step in management?

Transcript

Watch video only

Diabetes is one of the most common medical complications in pregnancy. Patients with diabetes in pregnancy are more likely to develop preeclampsia and undergo cesarean delivery. Additionally, higher glucose levels cross the placenta, resulting in an increased glucose supply to the fetus. The fetal pancreas responds by producing more insulin to handle the excess glucose. Fetal hyperinsulinemia promotes increased fat accumulation, particularly in the shoulders and chest, that can cause macrosomia; shoulder dystocia; and birth trauma.

Moreover, once the umbilical cord is clamped after delivery, the maternal glucose supply is interrupted, which can lead to neonatal hypoglycemia. Most cases of diabetes in pregnancy are gestational diabetes mellitus, or GDM, which is hyperglycemia that develops during pregnancy. However, many patients don’t receive diabetes screening before pregnancy, so it can be challenging to differentiate between GDM and previously existing, or pregestational, type 1 or type 2 diabetes.

The first step in evaluating a patient who presents for diabetes screening in pregnancy is to obtain a focused history and physical exam, ideally at the initiation of prenatal care. First, you want to assess whether a patient has a previous diagnosis of either type 1 or type 2 diabetes. If they do, that’s pregestational diabetes mellitus. This is an important distinction to make, because patients with pregestational diabetes are more likely to have significant maternal and fetal complications during pregnancy, and usually require additional monitoring.

On the flip side, if your patient has no previous diagnosis of type 1 or type 2 diabetes, your next step is to assess whether they’re at high risk for GDM. A patient who is at high risk will have an elevated BMI of at least 25, or at least 23 in patients of Asian descent; plus one or more additional risk factors. These additional risk factors in history include GDM in a previous pregnancy; a first-degree relative with diabetes; previous delivery of an infant weighing at least 4,000 grams or about 9 pounds; or a personal history of polycystic ovarian syndrome or cardiovascular disease.

Some additional risk factors can be discovered on physical examination, including hypertension, or prepregnancy morbid obesity with a BMI greater than 40. Finally, additional risk factors related to labs include a hemoglobin A1c of 5.7 % or greater, and certain abnormal lipid values, like an HDL lower than 35 mg/dL and triglycerides higher than 250 mg/dL.

All pregnant patients should be screened for GDM - it’s just a matter of when, which is based on assessment of risk factors. First, let’s talk about patients who are at “average risk” for GDM; meaning they have no additional risk factors for GDM. Average risk patients are screened at 24 to 28 weeks of gestation with a 50-gram, one-hour oral glucose tolerance test. A normal test result indicates that the patient does not have gestational diabetes and can proceed with routine prenatal care.

Here’s a clinical pearl! The cut-off value for a normal one-hour glucose test varies between 130 and 140 mg/dL because there isn’t enough evidence to determine the ideal threshold to screen for gestational diabetes. Each clinical site or institution should decide which cut-off to use for screening and remain consistent throughout their practice.

Alright, whichever screening cut-off is used, if the one-hour glucose test for an average-risk patient is elevated, the patient should then undergo a 100-gram, three-hour oral glucose tolerance test. This test includes a fasting glucose measurement as well as additional measurements at 1, 2, and 3 hours after consuming the glucose load.

Here’s a high-yield fact! A commonly used set of diagnostic thresholds for the three-hour glucose test is the Carpenter and Coustan criteria, which include normal glucose values of fasting below 95, a one-hour result below 180, a two-hour result below 155, and a three-hour result below 140. Another acceptable approach would be to use glucose values established by the National Diabetes Data Group, which are fasting less than 105, a one-hour less than 190, a two-hour less than 165, and a three-hour less than 145.

Okay, back to our patient. The three-hour test is considered normal if no more than one of the four values is elevated. A normal 3-hour test result at 24 to 28 weeks means that your patient does not have gestational diabetes and can resume routine prenatal care.

Sources

  1. "ACOG Practice Bulletin No. 201: Pregestational diabetes mellitus" Obstet Gynecol (2018)
  2. "ACOG Practice Bulletin No. 190: Gestational diabetes mellitus" Obstet Gynecol (2018)
  3. "Lifestyle interventions for the treatment of women with gestational diabetes" Cochrane Database Syst Rev (2017)